Cosmetic-Derived Mannosylerythritol Lipid-B-Phospholipid Nanoliposome: An Acid-Stabilized Carrier for Efficient Gastromucosal Delivery of Amoxicillin for In Vivo Treatment of Helicobacter pylori
Open Access
- 15 August 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (33) , 29086-29099
Abstract
Helicobacter pylori infection is a leading cause of gastritis and peptic ulcer. Current treatments for H. pylori are limited by the increase in antibiotic-resistant strains and low drug delivery to the infection site, indicating the need for effective delivery systems of antibiotics. Although liposomes are the most successful drug delivery carriers that have already been applied commercially, their acidic stability still stands as a problem. Herein, we developed a novel nanoliposome using cosmetic raw materials of mannosylerythritol lipid-B (MEL-B), soy bean lecithin, and cholesterol, namely, LipoSC-MELB. LipoSC-MELB exhibited enhanced stability under the simulated gastric-acid condition, owing to its strong intermolecular hydrogen-bond interactions caused by the incorporation of MEL-B. Moreover, amoxicillin-loaded LipoSC-MELB (LipoSC-MELB/AMX) had a particle size of approximately 100 nm and exhibited sustained drug release under varying pH conditions (pH 3-7). Besides, LipoSC-MELB/AMX exhibited significantly higher anti-H. pylori and anti-H. pylori biofilm activity as compared with free AMX. Furthermore, LipoSC-MELB was able to carry AMX across the barriers of gastric mucus and H. pylori biofilms. Remarkably, in vivo assays indicated that LipoSC-MELB/AMX was effective in treating H. pylori infection and its associated gastritis and gastric ulcers. Overall, the findings of this study showed that LipoSC-MELB was effective for gastromucosal delivery of amoxicillin to improve its bioavailability for the treatment of H. pylori infection.Keywords
Funding Information
- Natural Science Foundation of Shandong Province (ZR2018MC010)
This publication has 51 references indexed in Scilit:
- Eradication of Helicobacter pylori: Past, present and futureJournal of Controlled Release, 2014
- Preparation of Tween 80-Zn/Al-Levodopa-Layered Double Hydroxides Nanocomposite for Drug Delivery SystemThe Scientific World Journal, 2014
- The gastrointestinal mucus system in health and diseaseNature Reviews Gastroenterology & Hepatology, 2013
- A new method for determining acute toxicity in animal modelsToxicology International, 2013
- Glycosylated liposomes against Helicobacter pylori: Behavior in acidic conditionsBiochemical and Biophysical Research Communications, 2009
- Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissuesAdvanced Drug Delivery Reviews, 2009
- Polyelectrolyte Coated Multilayered Liposomes (Nanocapsules) for the Treatment of Helicobacter pylori InfectionMolecular Pharmaceutics, 2009
- Deficiencies of Myeloid Differentiation Factor 88, Toll-Like Receptor 2 (TLR2), or TLR4 Produce Specific Defects in Macrophage Cytokine Secretion Induced byHelicobacter pyloriInfection and Immunity, 2007
- GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene deliveryAdvanced Drug Delivery Reviews, 2004
- The spatial orientation of Helicobacter pylori in the gastric mucusProceedings of the National Academy of Sciences, 2004